Efpia Codes Transparency International

As recognized, adventure as capably as experience roughly lesson, amusement, as competently as covenant can be gotten by just checking out a ebook **Efpia Codes Transparency International** moreover it is not directly done, you could bow to even more vis--vis this life, in the region of the world.

We pay for you this proper as skillfully as easy pretentiousness to acquire those all. We have the funds for Efpia Codes Transparency International and numerous books collections from fictions to scientific research in any way. accompanied by them is this Efpia Codes Transparency International that can be your partner.

Medications in Single-Dose Vials - 2021

Ethical Criteria for Medicinal Drug Promotion - World Health Organization 1988 "Resolution WHA41.17 adopted by the Forty-first World Health Assembly, 13 May 1988" - p.1.

A Practical Approach to Pharmaceutical Policy - Andreas Seiter 2010-06-17 This book offers policy makers a hands-on approach, tested in the World Bank’s field work in many countries, for developing policies that

improve access to safe, effective medicines in health systems of low- and middle-income economies.

Patient Involvement in Health Technology Assessment - Karen M. Facey 2017-05-15

This is the first book to offer a comprehensive guide to involving patients in health technology assessment (HTA). Defining patient involvement as patient participation in the HTA process and research into patient aspects, this book includes detailed explanations of approaches to participation and research, as well as case studies. Patient Involvement in HTA enables researchers, postgraduate students, HTA professionals and experts in the HTA community to study these complementary ways of taking account of patients' knowledge, experiences, needs and preferences. Part I includes chapters discussing the ethical rationale, terminology, patient-based evidence, participation and patient input. Part II sets out methodology including: Qualitative Evidence Synthesis, Discrete Choice Experiments, Analytical Hierarchy Processes, Ethnographic Fieldwork, Deliberative Methods, Social Media Analysis, Patient-Reported Outcome Measures, patients as collaborative research partners and evaluation. Part III contains 15 case studies setting out current activities by HTA bodies on five continents, health technology developers and patient organisations. Each part includes discussion chapters from leading experts in patient involvement. A final chapter reflects on the

need to clearly define the goals for patient involvement within the context of the HTA to identify the optimal approach. With cohesive contributions from more than 80 authors from a variety of disciplines around the globe, it is hoped this book will serve as a catalyst for collaboration to further develop patient involvement to improve HTA. "If you’re not involving patients, you're not doing HTA!" - Dr. Brian O’Rourke, President and CEO of CADTH, Chair of INAHTA

Essential Writing, Communication and Narrative Skills for Medical Scientists Before and After the COVID Era - Gian Carlo Di Renzo 2022-01-02

When the COVID- 19 pandemic occurred, all the main communication systems of medical research have undergone an epochal change. Many online journals and magazines have tried to publish inherent works of this specific problem as soon as possible, soliciting and preferring them to others, thus changing the system of free acceptance of scientific works once. Moreover, the way to communicate these works has no longer occurred through standard Scientific Congresses but with other systems, websites/streaming and webinars or virtual conferences. Now there is something systematic missing, which foresees that this may last in the future, in the post COVID-19 era (AC): the communication system of the medical sciences will be different from now on. There will be far fewer classical-style conferences like the ones so popular before COVID-19 outbreak (BC) but there will be

more webinars, in streaming and virtual conferences. This new book fits well in this period, creating a bridge between those who do research, how it is communicated, what are the classic communication methods and what is all the necessary background to communicate with new tools. The book idea is based on the legacy left by Michael Faraday, the famous American chemist, who sensed how communicating what happens in science can make the difference between the success and failure of the research itself: “A lecturer should appear easy and collected, undaunted and unconcerned” “Lecturers which really teach will never be popular; lecturers which are popular will never really teach “ Michael Faraday, "Advice to lecturers", 1848 The volume approach is multidisciplinary and written by top experts in the field of communication and education. It will be a useful tool for scientists in this moment of epochal change in medical communication.

Advertising Food in Europe - Aude Mahy 2014

A large number of food law matters are handled differently by the various national jurisdictions within and outside of the European Union. This edited volume presents the various national approaches on how foodstuffs ought to be successfully marketed across the European Economic Area. Following a same framework, experienced food lawyers provide practical solutions and handy insight on the thorniest and crucial national aspects of food

advertising within their country. The book is therefore conceived as a practical manual, each chapter covering one specific country.

A Public Role for the Private Sector - Virginia Haufler 2013-01-25

Increasing economic competition combined with the powerful threat of transnational activism are pushing firms to develop new political strategies. Over the past decade a growing number of corporations have adopted policies of industry self-regulation—corporate codes of conduct, social and environmental standards, and auditing and monitoring systems. A Public Role for the Private Sector explores the phenomenon of industry self-regulation through three different cases—environment, labor, and information privacy—where corporate leaders appear to be converging on industry self-regulation as the appropriate response to competing pressures. Political and economic risks, reputational effects, and learning within the business community all influence the adoption of a self-regulatory strategy, but there are wide variations in the strength and character of it across industries and issue areas. Industry self-regulation raises significant questions about the place of the private sector in regulation and governance, and the accountability, legitimacy and power of industry at a time of rapid globalization.

Integrity of Scientific Research - Joel Faintuch 2022-10-13

This book provides a scientific and ethical approach to all forms of

fraud and misconduct focusing on a scholarly however practice-oriented description of the problems, roots and potential solutions. Organized in dedicated parts, an international team of experts systematically analyzes the most prevalent forms of misconduct, ghost writing, pseudo-science, dubious trials, predatory journals, fake news, mistreatment and harassment, in research, publications, at academic institutions, and in the professional and healthcare environment. A special focus is given to corrective interventions and the role of prevention, education and training. Comprehensive in its scope, the book offers an easy-to-read overview along with a number of real cases for experienced and novice personnel alike. The significance of scientific integrity and research ethics increased during the last couple of years and ethic committees and offices have become an integral part at universities, hospitals, research institutions, government agencies and major private organizations all over the world. Thus, this book provides an indispensable, comprehensive overview across disciplines and for everybody working in research and affiliated institutions.

Intellectual Property in the Life Sciences - Paul England 2015

Subjects explored within the national chapters include small molecules, secondary patents, DNA and biologicals, patent infringement and enforcement, compulsory licensing, branding and designs, counterfeiting and know-how protection,

and patenting and supplementary protection certificates (SPCs) in personalised medicine.

The Global Guide to Pharma Marketing Codes - Globalhealthpr 2008-03

The Global Guide to Pharma Marketing Codes will help marketers maximise public relations opportunities around the world. This publication provides an overview of basic healthcare promotional regulations, and answers the most frequently asked questions about what is and isn't permitted with respect to the media and third party involvement. This truly unique guide was produced with the insight and expertise of the largest independent public relations group dedicated exclusively to health and medical communications worldwide. GLOBALHealthPR (GHPR) is an international partnership uniting some of the world's most successful independent healthcare public relations firms and their affiliates from major markets in Europe, the Americas and Asia.

The Business of Healthcare Innovation - Lawton R. Burns 2005-08-25

The first wide-ranging analysis of business trends in the manufacturing segment of the health care industry.

Successfully Marketing Clinical Trial Results - Dr Günter Umbach 2012-09-28

In the US alone, pharmaceutical companies spend around $7 billion a year on clinical trials for drugs; all this in a global market where increasing competition and pressure on healthcare financing are both impacting on margins and profitability. One

solution for pharmaceutical companies lies within the clinical trials themselves. If only you can communicate the trial findings to the right people, in the right way, you can benefit from this huge investment and add significant value to your product range and your brand. Successfully Marketing Clinical Trials Results is a comprehensive guide for every marketing professional faced with the challenge of using marketing to convert scientific data into sales. The book offers you practical knowledge on how to use medical research data to maximise the revenue from your products. There are sections explaining how to: • identify your market and devise your strategy; • develop your content and translate data into a message that has impact; • use language, layout and illustrations to best effect; • communicate internally as well as externally; • make best use of the resources available; • align your sales force and the external agencies with whom you work; • lead the people in the project team; • co-operate with the medical researchers, external experts and the press. In this book are answers for everything from how to handle class-effect questions to developing a shared brand vocabulary. There are plenty of vivid examples and real-life applications to reinforce the ideas. Cases studies illustrate solutions to problems; checklists and tips will help to implement the suggestions and recommendations. Günter Umbach has distilled the essence both of 25 years' experience in the

healthcare market and of his highly successful seminar series on marketing clinical trials into the professional advice given in this book. The text is accompanied by a CD ROM containing detailed Powerpoint slides supporting each of the (over 300) techniques that you can use in your marketing team meetings to develop great ideas of your own.

Health System Performance Comparison: An Agenda For Policy, Information And Research - Papanicolas, Irene 2013-06-01

This book seeks to identify the current 'state of the art' of health system comparison, identifying data and methodological issues and exploring the current interface between evidence and practice.

Guide to EU Pharmaceutical Regulatory Law - Sally Shorthose 2017-02-17

In the European Union (EU) and its Member States, as elsewhere, the marketing of pharmaceuticals has become subject to an increasingly complex web of legislation and regulation, resulting from the intense scrutiny necessary to ensure such essential products are not only efficacious but safe. This useful volume lays out this system with extraordinary clarity and logic. Adopting a Europe-wide perspective on the law governing pharmaceuticals, expert authors from the law firm Bird & Bird LLP map the life cycle of a medicinal product or medical device from development to clinical trials to product launch and ongoing pharmacovigilance, offering comprehensive and unambiguous guidance

at every stage. A brief overview of how the proposed exit from the EU by the UK will affect the regulatory regime is also included. Following an introductory overview focusing on the regulatory framework for pharmaceuticals in Europe – from its underlying rationales to the relevant committees and agencies – each of fifteen incisive chapters examines a particular process or subject. Among the many topics and issues covered are the following: - obtaining a marketing authorisation; - stages and standards for creating a product dossier; - clinical trials; - how and when an abridged procedure can be used; - criteria for conditional marketing authorisations; - generic products and 'essential similarity'; - paediatric use and the requisite additional trials; - biologicals and 'biosimilars'; - homeopathic and herbal medicines; - reporting procedures; - pharmacovigilance; - parallel trade; - relevant competition law and intellectual property rights; and - advertising. In addition, national variation charts in many of the chapters illustrate eight major jurisdictions (Belgium, France, Germany, Italy, The Netherlands, Spain, Sweden, and the UK). Sample forms and URLs for the most important Directives are included. Pharmaceutical lawyers and regulatory advisers, both in-house and in private practice, will welcome this unique book. It offers immeasurable value for all who need to understand the process of bringing a medicinal product or medical

device to market and the continuing rights and obligations.

House of Commons - Science and Technology Committee: Clinical Trials - HC 104 - Great Britain: Parliament: House of Commons: Science and Technology Committee 2013-09-17 Many of the trials taking place today are unregistered and unpublished, meaning that the information that they generate remains invisible to both the scientific community and the public. This undermines public trust, slowing the pace of medical advancement and potentially putting patients at risk. All trials conducted on NHS treatments-and all other trials receiving public funding-should be prospectively registered and their results published in a scientific journal. While the focus should be on implementing this change for future trials, the Government must also do what it can to ensure that historic trials are registered and published, particularly where they have been publically funded. The Government should also take steps to facilitate greater sharing of the raw data generated during a trial in a responsible and controlled way, with the knowledge and consent of patients. The report also draws attention to the recent fall in the number of trials taking place in the UK. It finds that the need for multiple governance approvals from participating NHS organisations remained the biggest barrier to setting up a UK trial, but that lack of public awareness was also a key issue. Recruiting participants can also be

a challenge. The report calls on the Government to take its recommendations into account in ongoing discussions regarding the revision of European clinical trials legislation and in its response to the European Medicines Agency's consultation on the release of clinical trial data, which closes at the end of this month

The Sedated Society - James Davies 2017-01-23

This edited volume provides an answer to a rising public health concern: what drives the over prescription of psychiatric medication epidemic? Over 15% of the UK public takes a psychiatric medication on any given day, and the numbers are only set to increase. Placing this figure alongside the emerging clinical and scientific data revealing their poor outcomes and the harms these medications often cause, their commercial success cannot be explained by their therapeutic efficacy.Chapters from an interdisciplinary team of global experts in critical psychopharmacology rigorously examine how pharmaceutical sponsorship and marketing, diagnostic inflation, the manipulation and burying of negative clinical trials, lax medication regulation, and neoliberal public health policies have all been implicated in ever-rising psycho-pharmaceutical consumption. This volume will ignite a long-overdue public debate. It will be of interest to professionals in the field of mental health and researchers ranging from sociology of health, to medical anthropology and the

political economy of health.

Pharmaceutical Medicine and Translational Clinical Research - Divya Vohora 2017-11-14

Pharmaceutical Medicine and Translational Clinical Research covers clinical testing of medicines and the translation of pharmaceutical drug research into new medicines, also focusing on the need to understand the safety profile of medicine and the benefit-risk balance. Pharmacoeconomics and the social impact of healthcare on patients and public health are also featured. It is written in a clear and straightforward manner to enable rapid review and assimilation of complex information and contains reader-friendly features. As a greater understanding of these aspects is critical for students in the areas of pharmaceutical medicine, clinical research, pharmacology and pharmacy, as well as professionals working in the pharmaceutical industry, this book is an ideal resource. Includes detailed coverage of current trends and key topics in pharmaceutical medicine, including biosimilars, biobetters, super generics, and Provides a comprehensive look at current and important aspects of the science and regulation of drug and biologics discovery

The Textbook of Pharmaceutical Medicine - John P. Griffin 2009-10-15

The Textbook of Pharmaceutical Medicine is a standardreference for all those working in pharmaceutical medicine and therecognised text for the UK Faculty of Pharmaceutical MedicineDiploma. This is

a comprehensive volume covering the processes bywhich medicines are developed, tested and approved. Regulations fordrug development in the UK, EU, USA, Australia and Japan arediscussed, providing relevant information for drug approval in themain continents where new drugs are developed. The chapters are written by leading academics, medical directorsand lawyers, providing authoritative and in-depth information fortrainees on the Faculty course, and for physicians working in thepharmaceutical industry. As well as thorough updating of theregulatory chapters, the 6th edition includes chapters onthese vital new areas: Paediatric regulation Ethics Due diligence and the pharmaceutical physician

Health Technology Assessment in Japan - Isao Kamae 2019-09-03

Representing the first book on the topic, this work offers the reader an introduction to the Japanese systems for health technology assessment (HTA) officially introduced by the Ministry of Health, Labour and Welfare (MHLW) in 2016. Policy and guidelines are discussed, with the relevant methods and conditions of cost-effectiveness analysis explained alongside. Numerous instructive examples and exercises, ranging from basic to advanced, impart valuable knowledge and insight on the quantitative methods for economic evaluation, which will appeal to both beginners and experts. This guidebook is authored by Japan’s foremost expert in HTA and pharmacoeconomics, with a view to strengthening the

reader’s expertise in value-based healthcare and decision-making. The methods presented are essential to informing regulatory, local and patient decisions; as such, the book is equally recommended to industry and government, as well as academia, and anyone with an interest in Japanese HTA.

Rules and Guidance for Pharmaceutical Manufacturers and Distributors (Orange Guide) 2017 - Great Britain. Medicines and Healthcare products Regulatory Agency 2017-01-06

Familiarly known as the Orange Guide, this title is an essential reference work for all those involved in the manufacture and distribution of medicines in Europe. It is compiled by the UK drug regulatory body, MHRA, and brings together the European and UK guidance documents and information on legislation relating to the manufacture and distribution of medicines for human use. It contains EU guidance on good manufacturing and good distribution practice along with relevant information on EU and UK legislation. Changes in this new edition: Revised Annex 15. The revision of Annex 15 takes into account changes to other sections of the EudraLex, Volume 4, Part I, relationship to Part II, Annex 11, ICH Q8, Q9, Q10 and Q11, QWP guidance on process validation, and changes in manufacturing technology. Revised Annex 16. The GMP Guide Annex 16 has been revised to reflect the globalisation of the pharmaceutical supply chains and the introduction of new

quality control strategies. The revision has been carried out in the light of Directive 2011/62/EU amending Directive 2001/83/EC as regards the prevention of the entry into the legal supply chain of falsified medicinal products. This version also implements ICH Q8, Q9 and Q10 documents, and interpretation documents, such as the manufacturing and importation authorisation (MIA) interpretation document, as applicable. Also, some areas, where the interpretation by Member States has not been consistent, have been clarified. This revised Annex came into operation 15 April 2016. The introduction of guidelines on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities. The introduction of guidelines on the formalised risk assessment for ascertaining the appropriate GMP for excipients. The addition of the Guidelines on principles of Good Distribution Practice of active substances for medicinal products for human use (2015/C 95/01). These guidelines provide stand-alone guidance on Good Distribution Practice (GDP) for manufacturers, importers and distributors of active substances for medicinal products for human use. These guidelines should be followed as of 21 September 2015. The addition of the principles and guidelines of Good Manufacturing Practice (GMP) for active substances for medicinal products for human use, including active

substances intended for export. Revisions to the UK Human Medicines Regulations 2012. MHRA GMP Data Integrity Definitions and Guidance for Industry is now included which sets out MHRA expectations for data integrity in good manufacturing practice (GMP). The Guidance complements existing EU GMP guidance and should be read in conjunction with national medicines legislation and the GMP standards published in Eudralex volume.

The Life Sciences Law Review - Richard Kingham (Lawyer) 2022

The Internet of Things - Daniel Giusto 2010-03-10 This book constitutes the proceedings from the 20th Tyrrhenian Workshop on Digital Communications, held September 2009 in Pula, Sardinia, Italy and focused on the "Internet of Things."

Sharing Clinical Trial Data - Institute of Medicine 2015-04-20 Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health. Sharing Clinical

Trial Data presents activities and strategies for the responsible sharing of clinical trial data. With the goal of increasing scientific knowledge to lead to better therapies for patients, this book identifies guiding principles and makes recommendations to maximize the benefits and minimize risks. This report offers guidance on the types of clinical trial data available at different points in the process, the points in the process at which each type of data should be shared, methods for sharing data, what groups should have access to data, and future knowledge and infrastructure needs. Responsible sharing of clinical trial data will allow other investigators to replicate published findings and carry out additional analyses, strengthen the evidence base for regulatory and clinical decisions, and increase the scientific knowledge gained from investments by the funders of clinical trials. The recommendations of Sharing Clinical Trial Data will be useful both now and well into the future as improved sharing of data leads to a stronger evidence base for treatment. This book will be of interest to stakeholders across the spectrum of research--from funders, to researchers, to journals, to physicians, and ultimately, to patients.

Convergence and Hybrid Information Technology - Geuk Lee 2012-08-21

This book constitutes the refereed proceedings of the 6th International Conference on Convergence and Hybrid Information Technology,

ICHIT 2012, held in Daejeon, Korea, in August 2012. The 102 revised full papers presented were carefully reviewed and selected from 196 submissions. The papers are organized in topical sections on communications and networking; soft computing and intelligent systems; medical information and bioinformatics; security and safety systems; HCI and data mining; software and hardware engineering; image processing and pattern recognition; robotics and RFID technologies; convergence in information technology; workshop on advanced smart convergence (IWASC).

Guide to EU and UK Pharmaceutical Regulatory Law - Sally Shorthose 2023-01-10

In the European Union (EU), its Member States and the United Kingdom (UK) post-Brexit, as elsewhere, the marketing of pharmaceuticals is subject to an ever more complex web of legislation and regulation, resulting from the intense scrutiny necessary to ensure such essential products are not only efficacious but also safe. This useful volume lays out this system with extraordinary clarity and logic. Adopting a Europe-wide perspective on the law governing pharmaceuticals, expert authors from the law firm Bird & Bird LLP map the life cycle of a medicinal product or medical device from development to clinical trials to product launch and ongoing pharmacovigilance, offering comprehensive and unambiguous guidance at every stage. Following a brief overview of how the exit

from the EU by the UK currently affects the regulatory regime, as well as an introductory overview focusing on the regulatory framework for pharmaceuticals in Europe – from its underlying rationales to the relevant committees and agencies – each of the following twenty-one incisive chapters examines a particular process or subject. Among the many topics and issues covered from both an EU and UK perspective are the following: clinical trials; stages and standards for creating a product dossier; obtaining a marketing authorisation; how and when an abridged marketing authorisation procedure can be used; criteria for conditional marketing authorisations; generic products and 'essential similarity'; paediatric use and the requisite additional trials; orphan medicinal products; biologicals and 'biosimilars'; homeopathic, herbal and similar medicines; medical devices; pandemics, epidemics and vaccines; pharmacovigilance; parallel trade; advertising; and relevant competition law, intellectual property rights and data protection regulation. In addition, sample forms and URLs for the most important reference materials are included. Pharmaceutical lawyers and regulatory advisers, both in-house and in private practice, will welcome this unique book. It offers immeasurable value for all who need to understand the process of bringing a medicinal product or medical device to market and the continuing rights and obligations.

Practical Handbook on the 3Rs in the Context of the Directive 2010/63/EU - Gianni Dal Negro 2021-11-18 Practical Handbook on the 3Rs in the Context of the Directive 2010/63/EU provides updated information on the EU Directive 2010/63/EU, which is the European Union legislation that protects animals being used in research. EU Directive 2010/63/EU is the European Union (EU) legislation 'on the protection of animals used for scientific purposes' and is one of the most stringent ethical and welfare standards worldwide. Closes a gap in scientific literature by addressing the need for clear guidance in walking through the multifaced universe of 3Rs Offers a useful starting point for readers and scientist who approach the 3Rs for the first-time Gives insights into the harmonization of the animal research legislation across countries

Health Policy Brief - William W. Lowrance 1999

WHO Expert Committee on Specifications for Pharmaceutical Preparations - World Health Organization 2020-04-21

Institutional Corruption Theory in Pharmaceutical Industry-Medicine Relationships - Anna Laskai 2020-05-06 This book discusses the influence of the pharmaceutical industry on the practice of medicine, and the observed and potential pitfalls of such partnerships. It argues that the pharmaceutical industry has become indispensable to many of the activities of the

medical profession across the pharmaceutical product lifecycle, and examines the regulatory, ethical, professional and institutional difficulties that arise from these interactions. With data drawn from over 80 qualitative accounts from medical, pharmaceutical, regulatory and healthcare professionals, this book uses both Hungary and the Netherlands as case studies to demonstrate the potential problem of undue pharmaceutical industry influence within the relationships fostered with the profession of medicine. Chapters systematically describe the lifecycle of a pharmaceutical product from research to distribution, demonstrating the interdependency of industry and medicine. Arguing that the medical profession should be a buffer between the pharmaceutical industry interests and patient interests, the book explores how undue industry influence weakens the ability of the medical profession to do so. Using the theory of institutional corruption, the book aims to analyze how conflict of interest and the weakening of institutional imperatives is a result of institutional interactions rather than individual actions. Appropriate for students and researchers of the pharmaceutical industry, corporate corruption, and those working in NGOs and policy making, this unique volume is an comprehensive look at the complex relationship between medicine and pharmacy.

Global Corruption Report 2006 - Transparency International 2005-12-20

TI has once again shown its ability to combine research and policy analysis not just to shine a light on the deeply embedded problems of corruption ... but to propose progressive solutions. Former World Bank President James Wolfensohn on the Global Corruption ReportIn the health sector, corruption is a matter of life or death. It can take many forms: from medical professionals who sell medicines or services that should be freely available, to high-level government officials who embezzle money from health budgets, to pharmaceutical companies that buy influence over research agendas. The impact of corruption is always felt by the end user -- the sick person who is forced to pay over the odds or who is given unsafe, counterfeit medicines. The 2006 edition of Transparency International's Global Corruption Report shows the impact that corruption has on health care in rich and poor countries. From high-level bribery in Costa Rica to informal payments in Hungary, case studies from around the world explore the characteristics of the health sector that make it so prone to corruption. In a special section dedicated to corruption in HIV/AIDS, the report warns that the large sums being poured into fighting the world's deadliest diseases need to be safeguarded against abuse. There is also a detailed analysis of the problems of the pharmaceutical system.The report also offers an annual round-up of worldwide developments and tracks major trends in more

than 40 countries.The Global Corruption Report 2006 is the only report of its kind, and is an essential reference source for anyone who wants the latest research on how corruption affects everything from health to education and the oil and gas industries.

Democratizing Health - the late Hans Löfgren 2011-01-01

This book examines the important role of consumer activism in health policy in different national contexts. In an age of shifting boundaries between state and civil society, consumer groups are potentially drivers of democratisation in the health domain. The expert contributors explore how their activities bring new dynamics to relations between service providers, the medical profession, government agencies, and other policy actors. This book is unique in comprehensivelyanalysing the opportunities and dilemmas of this type of activism, including ambiguous partnerships between consumer groups and stakeholders such as the pharmaceutical industry. These themes are explored within aninternationally comparative framework, with case studies from various countries.

The Global Politics of Pharmaceutical Monopoly Power - Ellen F. M. 't Hoen 2009

In The Global Politics of Pharmaceutical Monopoly Power, researcher and global advocate Ellen 't Hoen explains how new global rules for pharmaceutical patenting impact access to medicines in the developing world. The book gives an account of the current debates on intellectual property,

access to medicines, and medical innovation, and provides historical context that explains how the current system emerged. This book supports major policy changes in the management of pharmaceutical patents and the way medical innovation is financed in order to protect public health and, in particular, promote access to essential medicines for all. The Open Society Institute provided support to translate this report into Russian.

Promoting Access to Medical Technologies and Innovation - Intersections between Public Health, Intellectual Property and Trade. - World Intellectual Property Organization 2020-07-28

This study seeks to reinforce the understanding of the interplay between the distinct policy domains of health, trade and intellectual property, and of how they affect medical innovation and access to medical technologies. The second edition comprehensively reviews new developments in key areas since the initial launch of the study in 2013.

Medicine Price Surveys, Analyses and Comparisons - Sabine Vogler 2018-10-23

Medicine Price Surveys, Analyses and Comparisons establishes guidelines for the study and implementation of pharmaceutical price surveys, analyses, and comparisons. Its contributors evaluate price survey literature, discuss the accessibility and reliability of data sources, and provide a checklist and training kit on conducting price surveys, analyses, and comparisons. Their

investigations survey price studies while accounting for the effects of methodologies and explaining regional differences in medicine prices. They also consider policy objectives such as affordable access to medicines and cost-containment as well as options for improving the effectiveness of policies. Provides guidance for planning and implementing pharmaceutical pricing policies and systems Reviews external price referencing systems Explains common baselines for interpreting price surveys Defines pharmaceutical price terminology and nomenclature

Business Ethics - A Philosophical and Behavioral Approach - Christian A. Conrad 2022-06-13

In this textbook we examine the extent to which moral values play a role as productive forces for companies and the economy as a whole, and explores the effect of ethical and unethical behavior at both levels. We show how ethics improves productivity, and provide specific ethics tools for practical application for both students and managers. Stemming from an overall interdisciplinary approach, this textbook fills a gap in the literature on ethics in business. Following a textbook structure, we first derive knowledge from scientific studies that are relevant for students, and then summarize the results. We explain ethical assessment approaches, and then provide an ethical assessment of economic behavior using case studies. Roleplaying and games

are used to explain the behavior of people in relation to ethics. The 2nd edition has been completely revised and expanded to include new findings from the behavioral sciences (psychology, social psychology, sociology and behavioral economics). In particular, the research on emotions, motivation and group behavior have given rise to many new impulses in business ethics. In addition, new case studies and new chapters were included, like Politics and Morality, Theories of Justice, Global Ethics, and Institutions as Solutions to Specific Game Situations (game theory). This book is important for students and researchers as well as policymakers and business executives due to its focus on applications.

Advocacy in Neurology - Wolfgang Grisold 2019-02-07

Advocacy is a broad term that covers activities aimed at increasing attention, awareness, information, nursing, treatment, and support to improve the outcome of patients. These actions can be focused directly towards patients or indirectly via third parties. Although advocacy is present in all medical specialties, neurology in particular finds itself in need of strong advocacy tools as the diagnosis, treatment, long-term care and associated resource, and social issues have become increasingly complex. While some physicians implicitly or explicitly act as advocates, there is a lack of holistic research in order to clarify the meaning of advocacy along with concrete methods and

strategies. Advocacy in Neurology provides an integrated approach to the concept of advocacy in neurology. Structured in five sections, the book begins by explaining the term "advocacy" in general before elaborating on the areas of interest within neurology. The text goes on to offer concrete strategies and tools for clinicians to deploy advocacy in their daily work, and then discusses specific neurological diseases to point out and explain where advocacy is, or could be, beneficial. The book ends with an outlook, presentation of results, and an ending conclusion. Advocacy in Neurology offers a practical perspective on advocacy activities in neurology, aiming to show when and why they are important for neurology.

Confronting Corruption - Fritz F. Heimann 2018 Mapping Modern Beijing investigates five methods of representing Beijing-a warped hometown, a city of snapshots and manners, an aesthetic city, an imperial capital in comparative and cross-cultural perspective, and a displaced city on the Sinophone and diasporic postmemory-by authors travelling across mainland China, Taiwan, Hong Kong, and overseas Sinophone and non-Chinese communities.

Global Business Regulation - John Braithwaite 2000-02-13 Across an amazing sweep of the critical areas of business regulation - from contract, intellectual property and corporations law, to trade, telecommunications, labour standards, drugs, food, transport and environment - this book confronts the question

of how the regulation of business has shifted from national to global institutions. Based on interviews with 500 international leaders in business and government, this book examines the role played by global institutions such as the WTO, the OECD, IMF, Moody's and the World Bank, as well as various NGOs and significant individuals. The authors argue that effective and decent global regulation depends on the determination of individuals to engage with powerful agendas and decision-making bodies that would otherwise be dominated by concentrated economic interests. This book will become a standard reference for readers in business, law, politics and international relations.

Der EFPIA-Kodex in der pharmazeutischen Industrie: Implementierung eines Controllingsystems zur Sicherstellung seiner Einhaltung - Franziska Protz 2015-06

Um Korruptionsrisiken effektiv vorzubeugen und das Vertrauen der Öffentlichkeit zu verbessern, plädieren Pharmaunternehmen für ein aktives Vorgehen gegen kriminelle Handlungsweisen im Gesundheitswesen. Der sog. EFPIA-Kodex des europäischen Dachverbandes der nationalen Verbände forschender Pharmaunternehmen ist eine der untergesetzlichen Normen, die durch Eigeninitiative in der Ärzteschaft und der Pharmabranche vorangetrieben werden, um integres Verhalten in den Mittelpunkt zu stellen. Mit diesem Kodex entschließen sich alle EFPIA-Mitglieder dazu, alle Zahlungen und

Zuwendungen aus ihren Geschäftsbeziehungen mit Fachkreisangehörigen und Organisationen des Gesundheitswesens detailliert zu veröffentlichen und der Gesellschaft frei zugänglich zu machen. Die vorliegende Arbeit befasst damit, welche Auswirkungen dieser Kodex auf die betroffenen Pharmaunternehmen hat, welche spezifischen Anforderungen an die Unternehmensführungen gestellt werden und wie den Kodex-Regelungen zur Umsetzung begegnet werden kann, um eine größtmögliche Transparenz zu schaffen.

New Perspectives on Regulation - David Moss 2009

As an experiment in reconnecting academia to the broader democracy, this work is designed to invigorate public policy debate by rededicating academic work to the pursuit of solutions to society's great problems.